Nanopath

Nanopath is a point-of-care molecular diagnostics company developing rapid testing for women's health, headquartered at The Engine built by MIT in Cambridge, Massachusetts. Its proprietary optical plasmonic biosensing platform detects molecular targets without nucleic acid amplification, enabling lab-quality results such as a 15-minute vaginitis assay during a single clinical visit. Founded in 2020 and led by co-founders Alison Burklund and Amogha Tadimety, the company is preparing an FDA 510(k) study for its vaginitis test, with potential expansion into STI and UTI testing.

  • Series B
  • Diagnostics
  • Healthtech
  • Medtech
  • Healthcare & Life Sciences

1

Round

1

Industry

4

Tags

Nov 10, 2026

Latest raise

Funding activity · 1 round

Raise timeline

  1. Nov 10, 2026

    $23M

    Series B

    Led by SV Health Investors

    • Gingerbread Capital
    • SV Health Investors
    • Elderberry Ventures
    • Labcorp Venture Fund
    • Norwest Venture Partners
    • Alumni Ventures

    Article coming soon.

Pricing

Research Nanopath — then scale the playbook

Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.

Enterprise

Custom pricing for unlimited scale. Let's talk.

Contact sales

Growth plan

For individuals and small teams getting started with AI buyer intelligence.

$149

/month

Features

  • Access to core AI adoption signals
  • 3–5 curated slices per week
  • 30–60 companies / week
  • AI Adoption Score
  • Deal-ready insights (why + pitch angle)
  • Basic filters (recency, slice, score)
  • CSV export
Most popular

Pro plan

For outbound teams and agencies that need more coverage and faster signal cadence.

$249

/month

Features

  • Everything in Growth, plus:
  • Full access to all slices
  • 60–120 companies / week
  • Higher-frequency signal updates
  • Priority / early signals (before Growth)
  • Advanced filters (industry, size, use case)
  • Deeper company insights
  • Faster export + bulk workflows

Act on this raise

See if Nanopath is moving on AI

Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.

© 2026 VeilStrat. All rights reserved.All systems operational